24.7.2025 08:30:01 CEST | Monsenso |
Investor Nyheder
University of Birmingham, Mental Health Mission Midlands Translational Centre, Birmingham and Solihull NHS Foundation Trust og Nottinghamshire Healthcare NHS Foundation implementerer Monsensos platform til DECODE-projektet for bedre forståelse af patienter med behandlingsresistent depression
Investornyhed nr. 1 -2025
København, den 24. juli 2025(Denne meddelelse indeholder intern information)
Monsenso A/S, en førende udbyder af digitale sundhedsløsninger, er stolte over at være den digitale teknologipartner i det britiske DECODE-projekt.Initiativet ledes af University of Birmingham i samarbejde med Mental Health Mission Midlands Translational Centre, Birmingham and Solihull NHS Foundation Trust og Nottinghamshire Healthcare NHS Foundation Trust. Projektet har til formål at forandre klinisk forskning og behandling af patienter med behandlingsresistent depression (TRD).
Monsensos digitale platform skal bruges til at rekruttere patienter målrettet, indsamle data fra patienternes eget hjem og måle kliniske resultater på en ensartet måde på tværs af flere NHS-enheder. Det skal bane vejen for mere præcis forskning i og fremtidige behandlinger af depression.
Et alvorligt sundhedsproblemBehandlingsresistent depression rammer næsten halvdelen af de patienter, der er diagnosticeret med svær depression – det vil sige, de ikke reagerer på mindst to forskellige former for antidepressiv medicin. TRD hænger ofte sammen med dårligere livskvalitet, flere sygdomme, højere risiko for selvmord og store samfundsøkonomiske omkostninger. [1]
DECODE-projektet vil opbygge en digital infrastruktur til rekruttering og monitorering af patienter, så man bedre kan identificere, forstå og behandle denne komplekse lidelse. Rekrutteringen forventes at starte i 3. kvartal 2025, og Monsensos platform får en central rolle i både den målrettede rekruttering og patientdataindsamlingen.
“Vi er meget glade for at støtte et så vigtigt nationalt initiativ, som fokuserer på en af de mest udfordrende områder inden for mental sundhed. Monsensos platform hjælper sundhedspersonale og forskere med at træffe bedre, datadrevne beslutninger gennem digital overvågning i realtid og standardiserede vurderinger,” siger Thomas Lethenborg, CEO i Monsenso. “Projektet bekræfter vores strategiske position som en erfaren partner i europæiske studier, hvor vigtige patientdata indsamles fra patienternes virkelige liv udenfor klinikken.”
Strategisk betydning for Monsenso
Udvidelse i Storbritannien: Styrker Monsensos tilstedeværelse i det britiske sundhedsvæsen, især i samarbejde med NHS og førende universiteter.
Skalerbar, digital forskningsmodel: Viser at Monsensos platform kan bruges i større, decentrale forskningsprojekter på flere steder samtidigt.
Mulighed for videre vækst: Projektet sigter mod geografisk ekspansion og flere præcisionsmedicinske studier.
Bekræftelse af produktets relevans: Understreger Monsensos evne til at levere digitale værktøjer, der opfylder behovene i moderne medicinsk og psykiatrisk forskning.
Steven Marwaha, Co-Director i Mental Health Mission Midlands Translational Centre og professor ved University of Birmingham, udtaler: ”Partnerskabet med Monsenso gør det nemmere og mere effektivt at rekruttere patienter og vurdere behandlingsresultater. Ved at bruge løbende dataindsamling, digitale værktøjer og ensartede målinger kan vi hurtigere opnå en bedre forståelse af behandlingsresistent depression og udvikle mere præcise og personlige behandlingsformer.”
Porjektet forventes ikke at påvirke Monsensos forventninger til finansåret 2025.[1]: University of Birmingham. “Nearly half of depression diagnoses could be considered treatment-resistant.” ScienceDaily. ScienceDaily, 21 March 2025. <www.sciencedaily.com/releases/2025/03/250321121442.htm>
Yderligere oplysninger:
Monsenso:
CEOThomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
HC Andersen CapitalBredgade 23, 21264 København K
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en digital sundhedsløsning til brug for decentaliserede forsøg, patientmonitorering og behandlingsunderstøttelse. Vores mission er at bidrage til bedre sundhed til flere personer og lavere omkostninger ved at understøtte behandling digitalt og bedre udnytte patienters egne data. Vores løsning bidrager til optimering af behandlingen og giver et detaljeret overblik over patienters sundhed via indsamling af data om deres tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig intervention. Vi samarbejder med sundhedsvæsenet, medicinalindustrien og forskningsinstitutioner verden over i vores forsøg på at levere løsninger som passer ind i patienters og sundhedsprofessionelles hverdag. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
Patient with smartphone.jpg
Clinician with clinical web portal.jpg
24.7.2025 08:30:01 CEST | Monsenso |
Investor News
University of Birmingham, Mental Health Mission Midlands Translational Centre, Birmingham and Solihull NHS Foundation Trust and Nottinghamshire Healthcare NHS Foundation implement Monsenso's digital health platform for the DECODE project, which aims to improve the understanding and treatment of treatment-resistant depression.
Investor News no. 1-2025
Copenhagen, 2025.07.24
(This message includes inside information)
Monsenso A/S, a leading provider of digital health solutions, is proud to announce its strategic role as the digital technology partner for the DECODE project in the United Kingdom.
The initiative, led by the University of Birmingham, in collaboration with the Mental Health Mission Midlands Translational Centre, Birmingham and Solihull NHS Foundation Trust, and Nottinghamshire Healthcare NHS Foundation Trust, is focused on transforming clinical research and care for patients with treatment-resistant depression (TRD).
As part of the project, Monsenso’s digital platform will enable stratified recruitment, remote patient data collection, and standardised clinical endpoint measurement across multiple NHS sites — laying the groundwork for improved precision in depression research and future interventions.
Addressing a Critical Public Health Challenge
Treatment-resistant depression (TRD) affects almost half of patients diagnosed with major depressive disorder meaning they do not respond to two or more oral antidepressants, and TRD is associated with poorer outcomes, including high comorbidity, suicidality, and economic burden. [1]
The DECODE project aims to build a digitally enabled recruitment and monitoring infrastructure to better identify, understand, and ultimately treat this complex condition.
Recruitment is expected to begin in Q3 2025, with Monsenso’s platform playing a pivotal role in data collection and patient stratification.
“We are honoured to support such an important national initiative addressing one of the most challenging areas in mental health. Monsenso’s platform is designed to help healthcare providers and researchers make better, data-driven decisions through real-time digital monitoring and standardised assessments,” says Thomas Lethenborg, CEO of Monsenso. “This project reaffirms our strategic positioning as a trusted partner in supporting decentralised, real-world data studies across Europe with healthcare, academic institutions and pharmaceuticals.”
Strategic Importance for Monsenso
Expansion into the UK: Strengthens Monsenso’s footprint within the UK healthcare ecosystem, particularly within the NHS and leading academic partners.
Scalable digital, decentralised research model: Demonstrates the scalability and flexibility of Monsenso’s platform for decentralised multi-site health research.
Expansion possibilities: The DECODE project has potential to pave the way for geographic expansion and follow-on precision-medicine studies.
Validation of product-market fit: Reinforces Monsenso’s role in delivering regulated, patient-centric digital tools that meet the complex needs of decentralised, real-world studies in psychiatric conditions and beyond.
Steven Marwaha, Co-director of the Midlands Mental Health Mission and Professor at the University of Birmingham, states: “This partnership with Monsenso enables us to streamline and enhance the way we recruit patients and assess outcomes. By integrating continuous data collection, digital phenotyping tools and standardising clinical endpoints, we can accelerate our understanding of treatment-resistant depression and drive more precise and personalised future interventions.”
The project is not expected to impact Monsenso’s projections for financial year 2025.
[1]: University of Birmingham. “Nearly half of depression diagnoses could be considered treatment-resistant.” ScienceDaily. ScienceDaily, 21 March 2025. <www.sciencedaily.com/releases/2025/03/250321121442.htm>
Further information:
Monsenso:
CEOThomas LethenborgTel. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
HC Andersen CapitalBredgade 23, 21264 København K
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise treatment and provides a detailed overview of an individual’s health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researchers worldwide in our endeavours to deliver solutions that fit into the lifes of patients and healthcare professionals. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
Patient with smartphone.jpg
Clinician with clinical web portal.jpg
